U.S. drug regulators have directed health care workers in eight states to stop using a COVID-19 treatment because it may not be effective against an Omicron coronavirus subvariant that’s rising in prevalence. The Food and Drug Administration (FDA) said sotrovimab, a monoclonal antibody used to treat COVID-19, can no longer be used in Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Rhode Island, and Vermont. Providers in Puerto Rico and the Virgin Islands also have been told to stop using stotrovimab. Regulators believe that the treatment, which was given emergency use authorization in May 2021, “is unlikely to be effective against the BA.2 subvariant,” the FDA said in a statement. BA.2 is a subvariant of Omicron, a variant of the CCP (Chinese Communist Party) virus, the pathogen that causes COVID-19. According to genomic surveillance conducted by the Centers for Disease Control and Prevention, BA.2 was responsible for 12.6 percent of … » Read full article
Bombshell Study – Popular Cooking Staple Linked to Memory Loss?
Aluminum Foil Is a Major Source of Aluminum Exposure, Studies Show Analysis by Dr. Joseph Mercola – November 06, 2024 Admin Note: foil is a staple for many and